The value of the serum ECP (eosinophil cationic protein) level for monitoring the treatment of allergic bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 268s Year: 2001
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
Serum eosinophil cationic protein as a marker of disease severity in patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001
Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
Ciclesonide 80 μg once daily reduces early and late asthmatic reaction, sputum eosinophils and serum ECP in asthma patients challenged with allergens Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Could eosinophil / neutrophil ratio be used to determine treatment in COPD patients? Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018
Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007
Comparisons of the eosinophil cationic protein (ECP) levels and eosinophil counts in sputum of mustard lung disease (MLD) and normal subjects Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Treatment: how does inflammatory phenotype influence response to treatment in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018
Role of sputum eosinophil levels in the assessment of asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
Theophylline drip infusion reduces peripheral blood eosinophil counts and ECP (eosinophil cationic protein) level on acute exacerbation of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
An investigation of apoptotic eosinophil numbers in induced sputum: is there an association with asthma severity? Source: Eur Respir J 2001; 18: Suppl. 33, 247s Year: 2001
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
The use of sputum differential cell counts and soluble phase measurements to assess airway inflammation in children with asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002
Serum ECP levels do not correlate with degree of bronchial hyperresponsiveness in patients with cough variant asthma Source: Eur Respir J 2005; 26: Suppl. 49, 584s Year: 2005
The eosinophil cationic protein/eosinophil count ratio as a marker of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002
IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status? Source: International Congress 2017 – Monitoring asthma control Year: 2017
Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response Source: Eur Respir J 2003; 22: 118-126 Year: 2003
Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019